Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mary Eapen
Long‐term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial
To the Editor: HLA-matched sibling donor transplantation accounts for the majority of transplants performed for sickle cell disease (SCD). However, only about 18% of patients in the United States with SCD will have unaffected human leukocyte antigen (HLA)-matched siblings or one with sickle trait, limiting applicability.
Journal of Clinical Oncology
1. Meisel R: Secondary malignancies after allogeneic hematopoietic stem cell transplantation for sickle cell disease inform gene therapy approaches. J Clin Oncol 41:3272-3273, 2023 Abstract, Google Scholar 2. Eapen M, Brazauskas R, Williams DA, et al: Secondary neoplasms after hematopoietic cell transplant for sickle cell disease. J Clin Oncol 41:2227-2237, 2023 Link, Google Scholar 3. Rizzo JD, Curtis RE, Socie G, et al: Solid cancers after allogeneic hematopoietic cell transplantation.
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial
Background Relapsed severe aplastic anaemia is a marrow failure disorder with high morbidity and mortality. It is often treated with bone marrow transplantation at relapse post-immunosuppressive therapy, but under-represented minorities often cannot find a suitably matched donor. This study aimed to understand the 1-year overall survival in patients with relapsed or refractory severe aplastic anaemia after haploidentical bone marrow transplantation.
A resurgence of cord blood transplantation?
Although the use of umbilical cord blood has increased access to transplantation for many individuals who otherwise would not have benefited from this treatment, selecting a suitably HLA-matched umbilical cord blood unit with an adequate cell dose remains a challenge for a substantial proportion of adults with haematological malignancies.
Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study
Summary Background Donors other than matched siblings and low-intensity conditioning regimens are increasingly used in haematopoietic stem cell transplantation. We aimed to compare the relative risk of donor type and conditioning regimen intensity on the transplantation outcomes of in patients with sickle cell disease. Methods For this retrospective cohort study, we collected data from 90 US centres reported to the Center for International Blood and Marrow Transplant Research.
In-vivo T-cell depletion: burden of morbidity versus survival
In The Lancet Haematology, in a phase 3 randomised trial, Francesca Bonifazi and colleagues 1 Bonifazi F Solano C Wolschke C et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematol.
Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis
Compared with HLA-matched transplantations, mortality was higher with transplantations mismatched at two (hazard ratio [HR] 1·55, 95% CI 1·08–2·21, p=0·018), three (2·04, 1·44–2·89, p=0·0001), and four or more alleles (3·15, 2·16–4·58, p<0·0001). There were no significant differences in mortality between transplantations that were matched and mismatched at one allele (HR 1·18, 95% CI 0·80–1·72, p=0·39).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mary
Contact Mary, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack